2 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
addressing a number of systematic implementation barriers Intervention directed at reducing blood glucose (BG)
in hospitals (11). These efforts contributed to a growing levels has resulted in improved outcomes in some, but not
national movement viewing the management of inpatient all, studies (5,18-25). Several recent clinical trials in criti-
hyperglycemia as a quality-of-care measure. cally ill patients have reported no reduction in mortality
Although hyperglycemia is associated with adverse from intensive treatment targeting near-euglycemia versus
patient outcomes, intervention to normalize glycemia conventional management targeting BG <180 mg/dL (<10.0
has yielded inconsistent results. Indeed, recent trials mmol/L). Of considerable concern are reports of harm, with
in critically ill patients have failed to show a significant higher rates of severe hypoglycemia and even increased
improvement in mortality with intensive glycemic control mortality (14) resulting from intensive glycemic control
(12,13) or have even shown increased mortality risk (14). (12-14,16,27,28). This variability in results may be attribut-
Moreover, these recent RCTs have highlighted the risk of able to several factors, including differences in intravenous
severe hypoglycemia resulting from such efforts (12-17). (IV) insulin treatment protocols and their implementation,
These outcomes have contributed to confusion regarding glycemic targets, patient populations, methods for glucose
specific glycemic targets and the means for achieving them monitoring, and insulin adjustment (12,29).
in both critically ill and noncritically ill patients. The following section focuses primarily on results of
Recognizing the importance of glycemic control across recent studies with RCT design that investigated patient
the continuum of care, AACE and ADA joined forces to outcomes with protocols targeting near-normalization of
develop this updated consensus statement on inpatient BG levels. Readers are referred to a previous ACE position
glycemic management. The central goals were to identify statement (9), an ACE/ADA consensus statement (11), and
reasonable, achievable, and safe glycemic targets and to a technical review (8) for details related to earlier studies
describe the protocols, procedures, and system improve- supporting inpatient glycemic management.
ments needed to facilitate their implementation. This docu-
ment is addressed to health care professionals, support- Data Derived From Surgical and
ing staff, hospital administrators, and other stakeholders Medical Intensive Care Units
focused on improved management of hyperglycemia in Observational studies have documented that hyper-
inpatient settings. Consensus panel members extensively glycemia after cardiothoracic surgical procedures is asso-
reviewed the most current literature and considered the fol- ciated with higher rates (approximately 2-fold) of wound
lowing questions: infection (20,30). Interventions to reduce hyperglycemia in
this setting with IV insulin therapy decrease infection rates
1. Does improving glycemic control improve clinical (19,21,31) and cardiac-related mortality (5,32), in compar-
outcomes for inpatients with hyperglycemia? ison with historical control subjects.
2. What glycemic targets can be recommended in differ- The results of several RCTs conducted in critically
ent patient populations? ill patients in medical and surgical intensive care units
3. What treatment options are available for achieving (ICUs) are summarized in Table 1 (5,13,14,16,27,28,33-
optimal glycemic targets safely and effectively in spe- 36). Intensive insulin therapy targeting arterial glucose
cific clinical situations? levels of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) in a primar-
4. Does inpatient management of hyperglycemia repre- ily surgical ICU patient population resulted in a significant
sent a safety concern? decrease in morbidity and mortality (5). However, imple-
5. What systems need to be in place to achieve these mentation of the identical protocol in 1,200 medical ICU
recommendations? patients by the same investigators in the same institution
6. Is treatment of inpatient hyperglycemia cost- effective? diminished morbidity but failed to reduce mortality. A 6-
7. What are the optimal strategies for transition to outpa- fold increase in severe hypoglycemic events (BG <40 mg/
tient care? dL [2.2 mmol/L]) was observed in the intensively treated
8. What are areas for future research? group (18.7% versus 3.1%), and hypoglycemia was identi-
fied as an independent risk factor for mortality (16).
QUESTION 1: Does improving glycemic control The Efficacy of Volume Substitution and Insulin
improve clinical outcomes for inpatients with Therapy in Severe Sepsis (VISEP) study reported no
hyperglycemia? decrease in mortality and higher rates of severe hypoglyce-
mia with intensive insulin therapy in patients with severe
Hyperglycemia in hospitalized patients, irrespective sepsis (17% versus 4.1%; P<.001) (13). Hypoglycemia—
of its cause, is unequivocally associated with adverse out- BG <40 mg/dL (<2.2 mmol/L)—was identified as an
comes (5,6,18-25). Hyperglycemia occurs in patients with independent risk factor for mortality (relative risk, 2.2 at
known or undiagnosed diabetes, or it occurs during acute 28 days; 95% confidence interval, 1.6 to 3.0) (Dr. Frank
illness in those with previously normal glucose tolerance Brunkhorst, personal communication, 2009). Similarly,
(termed “stress hyperglycemia”) (8,26). intensive glycemic control in a mixed medical and surgi-
Summary Data of Selected Randomized Controlled Trials of Intensive Insulin Therapy
in Critically Ill Patients (>200 Randomized Patients)a
Blood glucose target, Blood glucose achieved,b Odds
mg/dL (mmol/L) mg/dL (mmol/L) Primary End point rate ratioc
Trial N Setting Intensive Conventional Intensive Conventional outcome Intensive Conventional ARRc RRRc (95% CI)
DIGAMI (33), 1995 620 CCU 126-196 Usual care 173 211 1-year 18.6% 26.1% 7.5% 29%d NR
(AMI) (7-10.9) (9.6) (11.7) mortality
Van den Berghe et al 1,548 SICU 80-110 180-200 103 153 ICU 4.6% 8.0% 3.4% 42% 0.58d
(5), 2001 (4.4-6.1) (10-11) (5.7) (8.5) mortality (0.38-0.78)
DIGAMI 2 (34), 2005 1,253 CCU 126-180 Usual care 164 180 2-year Group 1, Group 3, …e …e NR
(AMI) (7-10) (group 3) (9.1) (10) mortality 23.4%; 17.9%
(groups 1 group 2,
& 2) 21.2%
Van den Berghe et al 1,200 MICU 80-110 180-200 111 153 Hospital 37.3% 40.0% 2.7% 7.0% 0.94e
(16), 2006 (4.4-6.1) (10-11) (6.2) (8.5) mortality (0.84-1.06)
HI-5 (35), 2006 240 CCU 72-180 Usual care 149 162 6-month 7.9% 6.1% −1.8%e −30%e NR
(AMI) (4-10) <288 (8.3) (9) mortality
GluControlf (27), 2007 1,101 ICU 80-110 140-180 118 144 ICU 16.7% 15.2% −1.5% −10% 1.10e
(4.4-6.1) (7.8-10) (6.5) (8) mortality (0.84-1.44)
Gandhi et al (36), 2007 399 Operating 80-110 <200 114 157 Compositeg 44% 46% 2% 4.3% 1.0e
room (4.4-6.1) (<11) (6.3) (8.7) (0.8-1.2)
VISEP (13), 2008 537h ICU 80-110 180-200 112 151 28-day 24.7% 26.0% 1.3% 5.0% 0.89e,i
(4.4-6.1) (10-11) (6.2) (8.4) mortality (0.58-1.38)
De La Rosa et alf (28), 504 SICU 80-110 180-200 117 148 28-day 36.6% 32.4% −4.2%e −13%e NR
2008 MICU (4.4-6.1) (10-11) (6.5) (8.2) mortality
NICE-SUGAR (14), 6,104 ICU 81-108 ≤180 115 145 3-month 27.5% 24.9% −2.6% −10.6% 1.14d
2009 (4.5-6) (≤10) (6.4) (8.0) mortality (1.02-1.28)
a AMI = acute myocardial infarction; ARR = absolute risk reduction; CCU = coronary care unit; CI = confidence interval; GIK = glucose-insulin-potassium; ICU = intensive care units (mixed);
MICU = medical intensive care unit(s); NR = not reported; RRR = relative risk reduction; SICU = surgical intensive care unit.
b Mean morning blood glucose concentrations
(except for GluControl, which reported mean overall blood glucose concentrations).
c Intensive group versus conventional group.
e Not significant (P>.05).
f Presented as abstract only.
g Composite of death, sternal infection, prolonged
ventilation, cardiac arrhythmias, stroke, and renal failure at 30 days.
h Only patients with sepsis.
i Personal communications, Dr. Frank Brunkhorst.
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
4 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
cal ICU resulted in no decrease in morbidity or mortality, Several studies have attempted to reproduce the favor-
while increasing the rate of hypoglycemia 5-fold (28). able outcomes observed with early implementation of insu-
The largest study to date, Normoglycemia in Intensive lin therapy reported in the first Diabetes and Insulin-Glucose
Care Evaluation—Survival Using Glucose Algorithm Infusion in Acute Myocardial Infarction (DIGAMI) trial
Regulation (NICE-SUGAR), a multicenter, multinational (33). DIGAMI 2, a multicenter RCT of 1,253 patients
RCT, tested the effect of tight glycemic control on out- with AMI and diabetes, failed to show a decrease in mor-
comes among 6,104 critically ill participants, the major- tality with such intervention (34). The Hyperglycemia
ity of whom (95%) required mechanical ventilation (14). Intensive Insulin Infusion in Infarction (HI-5) study ran-
The 90-day mortality was significantly higher in the inten- domly assigned patients with AMI to 24-hour infusions of
sively treated versus the conventionally treated group (78 insulin plus glucose for 24 hours (BG goal 180 mg/dL
more deaths; 27.5% versus 24.9%; P = .02) in both sur- [10.0 mmol/L]) or usual care. There were no significant
gical and medical patients. Mortality from cardiovascular differences in mortality, although there was a decreased
causes was more common in the intensively treated group incidence of congestive heart failure and reinfarction at
(76 more deaths; 41.6% versus 35.8%; P = .02). Severe 3 months in the intensively treated group (35). The very
hypoglycemia was also more common in the intensively large Clinical Trial of Reviparin and Metabolic Modulation
treated group (6.8% versus 0.5%; P.001). in Acute Myocardial Infarction Treatment Evaluation—
A recent meta-analysis of RCTs reported compari- Estudios Cardiologicos Latin America (CREATE-ECLA),
sons between intensive insulin therapy with glycemic tar- with 20,201 patients, tested the efficacy of glucose-insu-
gets of 72 to 126 mg/dL (4.0 to 7.0 mmol/L) (commonly, lin-potassium infusion in post-AMI patients and found no
80 to 110 mg/dL [4.4 to 6.1 mmol/L]) and less intensive decrease in mortality (44). A failure to achieve a prespeci-
therapy with targets of 150 to 220 mg/dL (8.3 to 12.2 fied glycemic target with intensive therapy that differed
mmol/L) (commonly, 180 to 200 mg/dL [10.0 to 11.1 from those in the control group may have contributed to
mmol/L]). Among 8,432 critically ill patients, there was these negative results (34,44).
no significant difference in mortality between intensive
therapy and control groups (21.6% versus 23.3%, respec- Data Derived From Other Critically Ill Patients
tively) (12). A decrease in septicemia and a 5-fold increase Several retrospective studies have examined the
in hypoglycemia (13.7% versus 2.5%) were observed. In relationship between glycemia and clinical outcomes in
a second meta-analysis (17) including 13,567 critically ill patients with extensive burns, body trauma, or traumatic
patients, a favorable effect of intensive therapy on mortal- brain injury or those who have undergone surgical treat-
ity was noted only in surgical ICU patients (relative risk, ment for cerebral aneurysms (45-53). In patients with
0.63; confidence interval, 0.44 to 0.91). There was a 6-fold subarachnoid hemorrhage, hyperglycemia was associated
increase in the rate of occurrence of hypoglycemia with with impaired cognition and deficits in gross neurologic
use of intensive therapy in all ICU patients (17). function at 3 months (52). Patients without diabetes who
The higher rates of severe hypoglycemia associated had severe blunt injury and hyperglycemia (BG 200
with intensive insulin therapy (12-14,16,27,28) raise the mg/dL [11.1 mmol/L]) were found to have a 2.2-fold
possibility that serious adverse events in the subgroup higher rate of mortality than those with admission glucose
of patients experiencing hypoglycemia offset, at least in of less than 200 mg/dL (11.1 mmol/L) (54). Similar find-
part, any benefit derived from strict glycemic control in ings have been reported by some investigators (55,56) but
the much larger subgroup of patients without hypoglyce- not others (57,58). In an RCT of tight glycemic control
mic events (13,16). Hypoglycemic events, however, have in 97 patients with severe traumatic brain injury (59), no
been infrequently linked to mortality; this finding suggests significant differences were noted in infections, 6-month
that severe hypoglycemia may be a marker of more serious mortality, or neurologic outcomes. The rate of occurrence
underlying disease (13,14,16). of hypoglycemia was 2-fold higher with use of intensive
Data Derived From Patients With
Acute Myocardial Infarction Data Derived From Patients
Although hyperglycemia is associated with adverse Undergoing Transplantation
outcomes after acute myocardial infarction (AMI) (37- Diabetes in patients after transplant procedures shares
41), reduction of glycemia per se, and not necessarily the many similarities with type 2 diabetes and is strongly asso-
use of insulin, is associated with improved outcomes (7). ciated with cardiovascular disease and cardiac death (60).
It remains unclear, however, whether hyperglycemia is Fuji et al (61) examined the effects of hyperglycemia dur-
a marker of underlying health status or is a mediator of ing neutropenic periods in 112 patients undergoing stem
complications after AMI. Non-iatrogenic hypoglycemia cell transplantation. Hyperglycemia was associated with
has also been associated with adverse outcomes and is a risk of organ failure, grade II to IV acute graft-versus-host
predictor of higher mortality (7,42,43). disease, and non-relapse-related mortality, but not with
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 5
infection or fever. A similar study in 382 patients reported nantly surgical ICU population (5), this target has been diffi-
that in those patients not treated with glucocorticoids during cult to achieve in subsequent studies, including the recently
neutropenia, each 10 mg/dL (0.6 mmol/L) increase in BG published NICE-SUGAR study (14), without increasing
was associated with a 1.15-fold increase in the odds ratio the risk for severe hypoglycemia (12,13,16,27,28). In addi-
for bacteremia (62). Hammer et al (63) analyzed BG lev- tion, there has been no consistent reduction in mortality
els among 1,175 adult patients receiving allogeneic hema- with intensive control of glycemia (12,17), and increased
topoietic cell transplants. Hyperglycemia, hypoglycemia, mortality was observed in the largest published study to
and glycemic variability all correlated with non-relapse- date (14). The reasons for this inconsistency are not entirely
related mortality within 200 days after transplantation. clear. The positive results reported in the initial studies may
have been attributable to differences in measurement and
Data Derived From Studies on Intraoperative reporting of BG values, selection of participants, glycemic
Glycemic Management variability, or nutritional support (12,17,84). Nevertheless,
In a double-blind, placebo-controlled RCT involving recent attempts to achieve tight glycemic control either
82 adults, intraoperative glucose-insulin-potassium infu- have not reduced or have actually increased mortality in
sion during a coronary artery bypass grafting procedure multicenter trials and clearly led to higher rates of hypo-
did not reduce myocardial damage, mortality, or length of glycemia (13,14,16).
stay (LOS) (64). In a study of 399 patients undergoing car- Despite the inconsistencies, it would be a serious error
diac surgical procedures, intensive insulin therapy (target to conclude that judicious control of glycemia in critically
BG, 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) intraoperatively ill patients, and in non-ICU patients in general, is not war-
resulted in no difference in patient outcomes; postopera- ranted. First, on the basis of a large number of studies in
tively, however, both groups were treated to similar glyce- a variety of inpatient settings, uncontrolled hyperglycemia
mic targets (36). clearly is associated with poor outcomes. Second, although
severe hypoglycemic events are observed in an unaccept-
Data Derived From Pediatric ICUs ably high number of patients receiving intensive insulin
Although outside the scope of this consensus statement, therapy with protocols targeting a BG of 80 to 110 mg/dL
it is worth noting that hyperglycemia (without diabetes) is (4.4 to 6.1 mmol/L) (12), this risk can likely be minimized
also common among pediatric patients with critical illness with relaxation of targets, improvement and standardization
(65-70), and it correlates with mortality (70). An interna- of protocols, and their careful implementation. Third, per-
tional, multicenter RCT, which tested the effect of inten- haps major beneficial effects on outcomes can be derived
sive glycemic control in very-low-birth-weight neonates, from a higher target range of glucose than 80 to 110 mg/dL
found higher rates of severe hypoglycemia and no signifi- in comparison with uncontrolled hyperglycemia.
cant difference in mortality or morbidity (71). In contrast, Finally, until further information becomes available,
another randomized trial conducted among 700 critically ill it is prudent to continue to emphasize the importance of
infants (n = 317) and children (n = 383) reported decreases glycemic control in hospitalized patients with critical and
in mortality, inflammatory markers, and LOS with use of
noncritical illness while aiming at targets that are less strin-
intensive insulin therapy, despite a greater frequency of
gent than 80 to 110 mg/dL (4.4 to 6.1 mmol/L), a topic that
severe hypoglycemia (25% versus 5%) (72).
is discussed in detail subsequently.
Hyperglycemia in Hospitalized Medical and
QUESTION 2: What glycemic targets can be
Surgical Patients in Non-ICU Settings
recommended in different patient populations?
No RCTs have examined the effect of intensive gly-
cemic control on outcomes in hospitalized patients outside
The management of hyperglycemia in the hospital
ICU settings. Several observational studies, however, point
presents unique challenges that stem from variations in a
to a strong association between hyperglycemia and poor
clinical outcomes, including prolonged hospital stay, infec- patient’s nutritional status and level of consciousness, the
tion, disability after discharge from the hospital, and death practical limitations of intermittent glycemic monitoring,
(4,7,35,73-81). and the ultimate importance of patient safety. Accordingly,
Several studies have found glucose variability to be an reasonable glucose targets in the hospital setting are mod-
independent predictor of mortality in critically ill patients estly higher than may be routinely advised for patients with
(63,66,82). Whether intervention to control glycemic vari- diabetes in the outpatient setting (85,86).
ability, per se, improves outcomes is not known (83).
Definition of Glucose Abnormalities
Summary of the Clinical Trials In this report, hyperglycemia is defined as any BG
Reviewed for Question 1 value 140 mg/dL (7.8 mmol/L). Levels that are signifi-
Overall, although a very tight glucose target (80 to 110 cantly and persistently above this level may necessitate
mg/dL [4.4 to 6.1 mmol/L]) was beneficial in a predomi- treatment in hospitalized patients. In patients without a
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
previous diagnosis of diabetes, elevated BG concentra- the aforementioned cut points. In contrast, higher glucose
tions may be due to stress hyperglycemia, a condition that ranges may be acceptable in terminally ill patients or in
can be established by a review of prior medical records or patients with severe comorbidities, as well as in those in
measurement of hemoglobin A1c. Hemoglobin A1c values patient-care settings where frequent glucose monitoring or
of 6.5% to 7.0% suggest that diabetes preceded hospital- close nursing supervision is not feasible.
ization (87). We emphasize that clinical judgment in combination
Hypoglycemia is defined as any BG level 70 mg/dL with ongoing assessment of the patient’s clinical status,
(3.9 mmol/L) (88). This is the standard definition in outpa- including changes in the trajectory of glucose measures,
tients and correlates with the initial threshold for the release the severity of illness, the nutritional status, or the concur-
of counterregulatory hormones (89). Severe hypoglycemia rent use of medications that might affect glucose levels (for
in hospitalized patients has been defined by many clinicians example, corticosteroids or octreotide), must be incorpo-
as 40 mg/dL (2.2 mmol/L), although this value is lower rated into the day-to-day decisions regarding insulin dos-
than the approximate 50 mg/dL (2.8 mmol/L) level at which ing (93,94).
cognitive impairment begins in normal persons (89-91). As
with hyperglycemia, hypoglycemia among inpatients is Inpatient Glucose Metrics
also associated with adverse short-term and long-term out- Hospitals attempting to improve the quality of their
comes. Early recognition and treatment of mild to moder- glycemic control and clinical investigators who analyze
ate hypoglycemia (40 and 69 mg/dL [2.2 and 3.8 mmol/L], glycemic management require standardized glucose mea-
respectively) can prevent deterioration to a more severe epi- sures for assessment of baseline performance and the effect
sode with potential adverse sequelae (91,92). of any intervention (11). Several methods have been pro-
posed for determining the adequacy of glycemic control
Treatment of Hyperglycemia in across a hospital or unit. A recent study indicated that a
Critically Ill Patients simple measure of mean BG (39) provides information
On the basis of the available evidence, insulin infusion similar to that from more complex metrics (hyperglycemic
should be used to control hyperglycemia in the majority index, time-averaged glucose) (14,48). The “patient-day”
of critically ill patients in the ICU setting, with a starting unit of measure is another proposed metric of hospital glu-
threshold of no higher than 180 mg/dL (10.0 mmol/L). cose data, especially when there is substantial variability in
Once IV insulin therapy has been initiated, the glucose the duration of hospital stay (95). The patient-day metric
level should be maintained between 140 and 180 mg/dL may yield a more accurate assessment of the frequency of
(7.8 and 10.0 mmol/L), and greater benefit may be realized hypoglycemia and severe hyperglycemic events, provid-
at the lower end of this range. Although strong evidence is ing an approach for obtaining measures of performance for
lacking, somewhat lower glucose targets may be appropri- clinical investigation (95).
ate in selected patients. Targets less than 110 mg/dL (6.1 The absolute definition of high-quality BG control has
mmol/L), however, are not recommended. Use of insulin not been determined. Of course, one should aim for the
infusion protocols with demonstrated safety and efficacy, highest percentage of patients within a prespecified BG tar-
resulting in low rates of occurrence of hypoglycemia, is get range. The opposite holds true for hypoglycemia. What
highly recommended. is reasonable for a hospital to achieve and with what con-
sistency have not been studied, and information regarding
Treatment of Hyperglycemia in best practices in this area is needed.
Noncritically Ill Patients
With no prospective, RCT data for establishing spe- QUESTION 3: What treatment options are
cific guidelines in noncritically ill patients, our recommen- available for achieving optimal glycemic targets
dations are based on clinical experience and judgment. For safely and effectively in specific clinical situations?
the majority of noncritically ill patients treated with insu-
lin, premeal glucose targets should generally be 140 mg/ In the hospital setting, insulin therapy is the preferred
dL (7.8 mmol/L) in conjunction with random BG values method for achieving glycemic control in most clinical
180 mg/dL (10.0 mmol/L), as long as these targets can situations (8). In the ICU, IV infusion is the preferred route
be safely achieved. For avoidance of hypoglycemia, con- of insulin administration. Outside of critical care units,
sideration should be given to reassessing the insulin regi- subcutaneous administration of insulin is used much more
men if BG levels decline below 100 mg/dL (5.6 mmol/L). frequently. Orally administered agents have a limited role
Modification of the regimen is necessary when BG values in the inpatient setting.
are 70 mg/dL (3.9 mmol/L), unless the event is easily
explained by other factors (such as a missed meal). Intravenous Insulin Infusions
Occasional clinically stable patients with a prior his- In the critical care setting, continuous IV insulin infu-
tory of successful tight glycemic control in the outpatient sion has been shown to be the most effective method for
setting may be maintained with a glucose range below achieving specific glycemic targets (8). Because of the
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
very short half-life of circulating insulin, IV delivery Injectable noninsulin therapies such as exenatide and
allows rapid dosing adjustments to address alterations in pramlintide have limitations similar to those with orally
the status of patients. administered agents in the hospital setting.
IV insulin therapy is ideally administered by means of
validated written or computerized protocols that allow for Specific Clinical Situations
predefined adjustments in the insulin infusion rate based Patients Using an Insulin Pump
on glycemic fluctuations and insulin dose. An extensive Patients who use continuous subcutaneous insulin
review of the merits and deficiencies of published proto- infusion (pump) therapy in the outpatient setting can be
cols is beyond the intent of this statement, and readers are candidates for diabetes self-management in the hospital,
referred to several available reports and reviews (96-101). provided they have the mental and physical capacity to
Continued education of staff in conjunction with periodic do so (8,103,114,115). Of importance, nursing personnel
ongoing review of patient data is critical for successful must document basal rates and bolus doses on a regular
implementation of any insulin protocol (97-101). basis (at least daily). The availability of hospital personnel
Patients who receive IV insulin infusions will usually with expertise in continuous subcutaneous insulin infusion
require transition to subcutaneously administered insulin therapy is essential (115).
when they begin eating regular meals or are transferred to
lower intensity care. Typically, a percentage (usually 75% Patients Receiving Enteral Nutrition
to 80%) of the total daily IV infusion dose is proportionately Hyperglycemia is a common side effect of inpatient
divided into basal and prandial components (see subse- enteral nutrition therapy (116,117). A recent study, in
quent material). Importantly, subcutaneously administered which a combination of basal insulin and correction insu-
insulin must be given 1 to 4 hours before discontinuation of lin was used, achieved a mean glucose value of 160 mg/dL
IV insulin therapy in order to prevent hyperglycemia (102). (8.9 mmol/L). Similar results were achieved in the group
Despite these recommendations, a safe and effective transi- randomized to receive SSI only; however, 48% of patients
tion regimen has not been substantiated. required the addition of intermediate-acting insulin to
achieve glycemic targets (109).
Subcutaneously Administered Insulin
Scheduled subcutaneous administration of insulin is Patients Receiving Parenteral Nutrition
the preferred method for achieving and maintaining glu- The high glucose load in standard parenteral nutrition
cose control in non-ICU patients with diabetes or stress frequently results in hyperglycemia, which is associated
hyperglycemia. The recommended components of inpa- with a higher incidence of complications and mortality in
tient subcutaneous insulin regimens are a basal, a nutri- critically ill patients in the ICU (118). Insulin therapy is
tional, and a supplemental (correction) element (8,103). highly recommended, with glucose targets as defined pre-
Each component can be met by one of several available viously on the basis of the severity of illness.
insulin products, depending on the particular hospital situ-
ation. Readers are referred to several recent publications Patients Receiving Glucocorticoid Therapy
and reviews that describe currently available insulin prepa- Hyperglycemia is a common complication of cor-
rations and protocols (101-106). ticosteroid therapy (93). Several approaches have been
A topic that deserves particular attention is the per- proposed for treatment of this condition, but no published
sistent overuse of what has been branded as sliding scale protocols or studies have investigated the efficacy of these
insulin (SSI) for management of hyperglycemia. The term approaches. A reasonable approach is to institute glucose
“correction insulin,” which refers to the use of additional monitoring for at least 48 hours in all patients receiving
short- or rapid-acting insulin in conjunction with scheduled high-dose glucocorticoid therapy and to initiate insulin
insulin doses to treat BG levels above desired targets, is therapy as appropriate (94). In patients who are already
preferred (8). Prolonged therapy with SSI as the sole regi- being treated for hyperglycemia, early adjustment of insu-
men is ineffective in the majority of patients (and poten- lin doses is recommended (119). Importantly, during cor-
tially dangerous in those with type 1 diabetes) (106-112). ticosteroid tapers, insulin dosing should be proactively
adjusted to avoid hypoglycemia.
Noninsulin agents are inappropriate in most hospital- QUESTION 4: Does inpatient management of
ized patients. Continued use of such agents may be appro- hyperglycemia represent a safety concern?
priate in selected stable patients who are expected to con-
sume meals at regular intervals. Caution must be exercised Overtreatment and undertreatment of hyperglycemia
with use of metformin because of the potential develop- represent major safety issues in hospitalized patients with
ment of a contraindication during the hospitalization, such and without diabetes (90,120,121). Fear of hypoglycemia,
as renal insufficiency, unstable hemodynamic status, or clinical inertia, and medical errors are major barriers to
need for imaging studies with radiocontrast dye (8,113). achieving optimal blood glucose control (90,122-131).
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
In most clinical situations, safe and reasonable glycemic Blood Glucose Monitoring
control can be achieved with appropriate use of insulin, Bedside BG monitoring with use of point-of-care
adjusted according to results of bedside glucose monitor- (POC) glucose meters is performed before meals and at
ing (102,106,109). bedtime in most inpatients who are eating usual meals. It
Clinical situations that increase the risk for hypo- is important to avoid routine use of correction insulin at
glycemia and hyperglycemia in the hospital include the bedtime. In patients who are receiving continuous enteral
following: or parenteral nutrition, glucose monitoring is optimally
performed every 4 to 6 hours. In patients who are receiv-
1. Changes in caloric or carbohydrate intake (“nothing ing cycled enteral nutrition or parenteral nutrition, the
by mouth” status, enteral nutrition, or parenteral nutri- schedule for glucose monitoring can be individualized but
tion) (94,128) should be frequent enough to detect hyperglycemia during
2. Change in clinical status or medications (for example, feedings and the risk of hypoglycemia when feedings are
corticosteroids or vasopressors) (93,98) interrupted (109,112). More frequent BG testing, ranging
3. Failure of the clinician to make adjustments to glyce- from every 30 minutes to every 2 hours, is required for
mic therapy based on daily BG patterns (102,128) patients receiving IV insulin infusions.
4. Prolonged use of SSI as monotherapy (107,108)
5. Poor coordination of BG testing and administration of Glucose Meters
insulin with meals (121,129) Safe and rational glycemic management relies on the
6. Poor communication during times of patient transfer accuracy of BG measurements performed with use of POC
to different care teams (120,121) glucose meters, which have several important limitations.
7. Use of long-acting sulfonylureas in elderly patients Although the US Food and Drug Administration allows a
and those with kidney or liver insufficiency ±20% error for glucose meters, questions have been raised
8. Errors in order writing and transcription (102,120) about the appropriateness of this criterion (138). Glucose
measurements differ significantly between plasma and
Hypoglycemia is a major safety concern with use whole blood, terms that are often used interchangeably and
of insulin and insulin secretagogues. Hypoglycemia can can lead to misinterpretation. Most commercially available
occur spontaneously in patients with sepsis (130) or in capillary glucose meters introduce a correction factor of
patients who receive certain medications, including quin- approximately 1.12 to report a “plasma adjusted” value
olone antibiotics and β-adrenergic agonists. Although not (139).
all hypoglycemic episodes are avoidable, the use of nurse-
Significant discrepancies among capillary, venous,
driven hypoglycemia treatment protocols that prompt early
and arterial plasma samples have been observed in patients
therapy for any BG levels 70 mg/dL (3.9 mmol/L) can
with low or high hemoglobin concentrations, hypoperfu-
prevent deterioration of potentially mild events—for exam-
sion, or the presence of interfering substances (139,140).
ple, BG values of 60 to 69 mg/dL (3.3 to 3.8 mmol/L)—to
Analytical variability has been described with several POC
more severe events—for example, BG concentrations 40
glucose meters (141). Any glucose result that does not cor-
mg/dL (2.2 mmol/L) (90-92,98,131). Particular attention
relate with the patient’s clinical status should be confirmed
is required in high-risk patients, including those with mal-
through conventional laboratory sampling of plasma
nutrition; advanced age; a history of severe hypoglycemia
(88,132); or autonomic, kidney, liver, or cardiac failure. glucose.
Clinical inertia can be defined as not adjusting glyce- Although laboratory measurement of plasma glucose
mic therapy in response to persistently abnormal results has less variability and interference, multiple daily phle-
on BG determination (123). Often, there is a lack of own- botomies are not practical. Moreover, the use of indwelling
ership for diabetes management, particularly in hospital- lines as the sampling source poses risks for infection. Studies
ized patients admitted with a primary diagnosis other than performed with use of continuous interstitial glucose moni-
diabetes (128). This inaction may be due in part to insuf- toring systems in the critical care setting (142,143) currently
ficient knowledge or confidence in diabetes management are limited by the lack of reliability of BG measurements in
(123,133). Improvements in care can be achieved by ongo- the hypoglycemic range as well as by cost.
ing education and training (134,135).
QUESTION 5: What systems need to be in place to
Insulin Errors achieve these recommendations?
Insulin has consistently been designated as a high-alert
medication because of the risk of harm that can accom- The complexity of inpatient glycemic management
pany errors in prescribing, transcribing, or dosing (136). necessitates a systems approach that facilitates safe prac-
The true frequency of such errors is unknown because the tices and reduces the risk for errors (120,121). Systems that
available data sources depend on voluntary reporting of facilitate the appropriate use of scheduled insulin therapy,
errors (102,137) and mechanisms for real-time root-cause with institutional support for inpatient personnel who are
analysis are not available in most hospitals. knowledgeable in glycemic management, are essential for
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 9
achieving safe and reasonable levels of glycemic control to an increase in time needed from physicians, nurses, phar-
in hospitalized patients. Readers are referred to the 2006 macists, and other services. These costs are best viewed as
ACE/ADA consensus statement, which outlines the sys- short-term investments that ultimately provide long-term
tems that must be in place to promote effective glycemic cost savings because of improved clinical outcomes, with
management in the hospital (11). Some of these recommen- observed decreases in LOS, inpatient complications, and
dations are reviewed briefly in the following paragraphs. need for rehospitalization (148-155).
The success of any glycemic management program Pharmacoeconomic analyses have examined the cost-
depends on the ability to obtain financial support from effectiveness of improved glycemic control in the hospital
hospital administrators, who should be made aware of the setting (148,149). In the Portland Diabetic Project, a 17-
potential for cost savings with reductions in morbidity, year prospective nonrandomized study of 4,864 patients
durations of hospital stay, and need for readmission. This with diabetes who underwent open heart surgical pro-
support is necessary for covering the costs of staff edu- cedures, institution of continuous IV insulin therapy to
cation, equipment, and personnel to oversee an inpatient achieve predetermined target BG levels reduced the inci-
diabetes management program (144). dence of deep sternal wound infections by 66%, resulting
The creation of a multidisciplinary steering committee in a total net savings to the hospital of $4,638 per patient
guided by local diabetes experts can establish reasonable (148). In another study, intensive glycemic control in 1,600
and achievable glycemic management goals with use of patients treated in a medical ICU was associated with a
protocols and order sets (90). Preprinted order sets or com- total cost savings of $1,580 per patient (149). Van den
puterized ordering systems with adequate technical sup- Berghe et al (150) reported cost savings of $3,476 (US dol-
port are useful tools for facilitating appropriate glycemic lars) per patient by strict normalization of BG levels with
therapy (8,11,145). These tools can advance orders that use of a post hoc health care resource utilization analysis
contain contingencies that promote patient safety, such as of their randomized mechanically ventilated surgical ICU
withholding prandial insulin if a patient will not eat (102). patients. In a retrospective analysis of patients undergoing
Protocols need to be reviewed periodically and revised in coronary artery bypass grafting, each 50 mg/dL (2.8 mmol/
accordance with available evidence. L) increase in BG values on the day of and after the surgi-
Inpatient providers often have insufficient knowledge cal procedure was associated with an increase in hospital
about the many aspects of inpatient diabetes care (133). cost of $1,769 and an increase in duration of hospital stay
Thus, education of personnel is essential, especially early of 0.76 day (151). In a tertiary care trauma center, imple-
during the implementation phase (101,127). Formal com- mentation of a diabetes management program to reduce the
munication among various disciplines and services helps monthly mean BG level by 26 mg/dL (1.4 mmol/L) (177
to garner support from hospital personnel for new practices mg/dL to 151 mg/dL [9.8 to 8.4 mmol/L]) resulted in sig-
and protocols, as well as providing a venue for identifying nificant reductions in LOS (0.26 day) in association with
concerns. estimated hospital savings of more than $2 million per year
Many hospitals are challenged by poor coordination (152). In another study, implementation of a subcutaneous
of meal delivery and prandial insulin administration (130), insulin protocol for treatment of patients with hyperglyce-
as well as variability in the carbohydrate content of meals mia in the emergency department resulted in a subsequent
(94). Ensuring appropriate administration of insulin with reduction of hospital stay by 1.5 days (153).
respect to meals despite variations in food delivery neces- The use of an intensified inpatient protocol by a diabe-
sitates coordination between dietary and nursing services tes management team resulted in correct coding and treat-
(122). A systems approach can also promote the coordi- ment of patients with previously unrecognized hyperglyce-
nation of glucose monitoring, insulin administration, and mia. The LOS was reduced for both primary and secondary
meal delivery, particularly during change of shifts and diagnoses of diabetes, and readmission rates declined (154).
times of patient transfer (121,122). In a different study, the use of diabetes team consultation
Electronic health records and computerized physi- resulted in a 56% reduction in LOS and a cost reduction of
cian order entry systems have the potential to improve the $2,353 per patient (155).
sharing of information, including POC glucose results and Thus, intensive glycemic control programs have
associated medication administration—which can contrib- reported substantial cost savings, primarily attributable
ute to the reduction of medical errors. These systems can to decreases in laboratory, pharmacy, and radiology costs;
also provide access to algorithms, protocols, and decision fewer inpatient complications; decreased ventilator days;
support tools that can help guide therapy (146,147). and reductions in ICU and hospital LOS.
These reports demonstrate that optimization of inpa-
QUESTION 6: Is treatment of inpatient tient glycemic management not only is effective in reduc-
hyperglycemia cost-effective? ing morbidity and mortality but also is cost-effective. The
business case for hospital support of glycemic manage-
A program of inpatient glycemic control with prespeci- ment programs is based on opportunities for improving the
fied glycemic targets will have associated costs attributable accuracy of documentation and coding for diabetes-related
10 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
diagnoses. The case for revenue generation through billing Medication errors and adverse drug events have been
for clinical services is based on opportunities to increase linked to poor communication of instructions to the patient
the provision of glycemic management services in the at the time of discharge (156,157). This is particularly true
hospital. It is imperative to involve hospital administra- for insulin regimens, which are inherently more complex.
tion in providing the necessary financial support for inpa- Because the day of discharge is not always conducive
tient glycemic management programs that will ultimately to retention of verbal instructions (158), clearly written
result in cost savings in conjunction with improved patient instructions provide a reference for patients and their out-
outcomes. patient providers, and they provide a format for medication
reconciliation between inpatient and outpatient settings. In
QUESTION 7: What are the optimal strategies for one recent study, an insulin-specific discharge instruction
transition to outpatient care? form provided greater clarity and more consistent direc-
tions for insulin dosing and self-testing of BG in compari-
Preparation for transition to the outpatient setting is son with a generic hospital discharge form (159).
an important goal of inpatient diabetes management and An outpatient follow-up visit with the primary care
begins with the hospital admission. This entails a funda- provider, endocrinologist, or diabetes educator within 1
mental shift in responsibility from a situation in which hos- month after discharge from the hospital is advised for all
pital personnel provide the diabetes care to one in which the patients having hyperglycemia in the hospital (8). Clear
patient is capable of self-management. Successful coordi- communication with outpatient providers either directly
nation of this transition requires a team approach that may or by means of hospital discharge summaries facilitates
involve physicians, nurses, medical assistants, dietitians, safe transitions to outpatient care. Providing information
case-managers, and social workers (8). Hospitals with cer- regarding the cause or the plan for determining the cause of
tified diabetes educators benefit from their expertise during hyperglycemia, related complications and comorbidities,
the discharge process. and recommended treatments can assist outpatient provid-
Admission assessment obtains information regarding ers as they assume ongoing care.
any prior history of diabetes or hyperglycemia, its man-
agement, and the level of glycemic control. Early assess- QUESTION 8: What are areas for future research?
ment of a patient’s cognitive abilities, literacy level, visual
acuity, dexterity, cultural context, and financial resources The following are selected research topics and ques-
for acquiring outpatient diabetic supplies allows sufficient tions proposed for guiding the management of patients
time to prepare the patient and address problem areas. with hyperglycemia in various hospital settings.
Hospitalization provides a unique opportunity for
addressing a patient’s education in diabetes self-manage- Stress Hyperglycemia
ment (3). Because the mean hospital LOS is usually less • What are the underlying mechanisms?
than 5 days (2) and the capacity to learn new material may • What abnormalities lead to variability in insulin resis-
be limited during acute illness, diabetes-related education tance observed in some critically ill patients?
is frequently limited to an inventory of basic “survival • What therapeutic modalities, in addition to glyce-
skills.” mic control, would improve outcomes in critically ill
It is recommended that the following areas be reviewed patients with hyperglycemia?
and addressed before the patient is discharged from the • Are there optimal and safe glycemic targets specific to
hospital (8): certain populations of critically ill patients?
• Level of understanding related to the diagnosis of Severe Hypoglycemia
diabetes • What is the profile of inpatients at greatest risk for
• Self-monitoring of BG and explanation of home BG severe hypoglycemia?
goals • What are the short-term and long-term outcomes of
• Definition, recognition, treatment, and prevention of patients experiencing severe hypoglycemia?
hyperglycemia and hypoglycemia • What are the true costs of inpatient hypoglycemia?
• Identification of health care provider who will be
responsible for diabetes care after discharge Glycemic Targets on General Medical
• Information on consistent eating patterns and Surgical Wards
• When and how to take BG-lowering medications, • What are optimal and safe glycemic targets in non-
including administration of insulin (if the patient is critically ill patients on medical and surgical wards?
receiving insulin for ongoing management at home) Recommended end points for an RCT include rates of
• Sick-day management hypoglycemia, hospital-acquired infections, other in-
• Proper use and disposal of needles and syringes hospital complications, LOS, and readmission.
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 11
Glycemic Variability Insulin Treatment and Monitoring Instruments
• What is the effect of glycemic variability and the rate • What are safe and effective strategies for inpatient use
of change in glycemia on short-term and long-term out- of insulin and insulin analogues?
comes, both in ICU and non-ICU settings? • What is the role of continuous glucose monitoring sys-
tems in inpatient settings?
Hospital Systems and Safety
• What hospital systems and safety measures are important
for improving glycemic control and patient outcomes? Pediatric Inpatient Populations
• What teams and support systems are required for safe and • What are the optimal and safe glycemic targets in non-
effective transition of patients to the outpatient setting? critically ill hospitalized children?
SUMMARY OF RECOMMENDATIONS
I. Critically Ill Patients • Clinical judgment and ongoing assessment of clinical
• Insulin therapy should be initiated for treatment of status must be incorporated into day-to-day decisions
persistent hyperglycemia, starting at a threshold of no regarding treatment of hyperglycemia.
greater than 180 mg/dL (10.0 mmol/L).
• Once insulin therapy has been started, a glucose range
III. Safety Issues
of 140 to 180 mg/dL (7.8 to 10.0 mmol/L) is recom-
• Overtreatment and undertreatment of hyperglycemia
mended for the majority of critically ill patients.
represent major safety concerns.
• Intravenous insulin infusions are the preferred method
• Education of hospital personnel is essential in engag-
for achieving and maintaining glycemic control in
ing the support of those involved in the care of inpa-
critically ill patients.
tients with hyperglycemia.
• Validated insulin infusion protocols with demonstrated
• Caution is required in interpreting results of POC glu-
safety and efficacy, and with low rates of occurrence
cose meters in patients with anemia, polycythemia,
of hypoglycemia, are recommended.
hypoperfusion, or use of some medications.
• With IV insulin therapy, frequent glucose monitoring
• Buy-in and financial support from hospital adminis-
is essential to minimize the occurrence of hypoglyce-
tration are required for promoting a rational systems
mia and to achieve optimal glucose control.
approach to inpatient glycemic management.
II. Noncritically Ill Patients
• For the majority of noncritically ill patients treated IV. Cost
with insulin, the premeal BG target should generally • Appropriate inpatient management of hyperglycemia
be 140 mg/dL (7.8 mmol/L) in conjunction with is cost-effective.
random BG values 180 mg/dL (10.0 mmol/L), pro-
vided these targets can be safely achieved.
• More stringent targets may be appropriate in stable V. Discharge Planning
patients with previous tight glycemic control. • Preparation for transition to the outpatient setting
• Less stringent targets may be appropriate in terminally should begin at the time of hospital admission.
ill patients or in patients with severe comorbidities. • Discharge planning, patient education, and clear com-
• Scheduled subcutaneous administration of insulin, munication with outpatient providers are critical for
with basal, nutritional, and correction components, is ensuring a safe and successful transition to outpatient
the preferred method for achieving and maintaining glycemic management.
• Prolonged therapy with SSI as the sole regimen is VI. Needed Research
discouraged. • A selected number of research questions and topics for
• Noninsulin antihyperglycemic agents are not appropri- guiding the management of inpatient hyperglycemia
ate in most hospitalized patients who require therapy in various hospital settings are proposed.
12 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
ACKNOWLEDGMENT 4. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler
LM, Kitabchi AE. Hyperglycemia: an independent marker
We acknowledge the medical writing assistance of of in-hospital mortality in patients with undiagnosed diabe-
Kate Mann, PharmD. tes. J Clin Endocrinol Metab. 2002;87:978-982.
5. Van den Berghe G, Wouters P, Weekers F, et al. Intensive
insulin therapy in critically ill patients. N Engl J Med. 2001;
6. Malmberg K, Norhammar A, Wedel H, et al.
Ms. Monica DiNardo reports that she has received Glycometabolic state at admission: important risk marker
consultant fees from sanofi-aventis U.S. LLC. of mortality in conventionally treated patients with dia-
Dr. Daniel Einhorn reports that he has received con- betes mellitus and acute myocardial infarction; long-term
sultant fees from Merck Co., Inc., consultant fees and results from the Diabetes and Insulin-Glucose Infusion in
research grant support from Amylin Pharmaceuticals, Inc., Acute Myocardial Infarction (DIGAMI) study. Circulation.
sanofi-aventis U.S. LLC, and Takeda Pharmaceuticals 1999;99:2626-2632.
North America, Inc., and research grant support from 7. Kosiborod M, Inzucchi SE, Goyal A, et al. The relation-
AstraZeneca 2009, GlaxoSmithKline, Johnson Johnson ship between spontaneous and iatrogenic hypoglycemia
and mortality in patients hospitalized with acute myocardial
Services, Inc., Eli Lilly Company, Medtronic, Inc., and
infarction [abstract]. Circulation. 2008;118(suppl):S1109.
Novo Nordisk A/S and is a stockholder with Halozyme
8. Clement S, Braithwaite SS, Magee MF (American
Therapeutics and MannKind Corporation. Diabetes Association Diabetes in Hospitals Writing
Dr. Richard Hellman reports that he has no relevant Committee). Management of diabetes and hyperglycemia
conflicts of interest. in hospitals [published corrections appear in Diabetes Care.
Dr. Irl B. Hirsch reports that he has received consul- 2004;27:856 and Diabetes Care. 2004;27:1255]. Diabetes
tant fees from Abbott Laboratories, F. Hoffman La Roche Care. 2004;27:553-591.
Ltd. (Roche), Johnson Johnson Services, Inc., and Novo 9. Garber AJ, Moghissi ES, Bransome ED Jr, et al
Nordisk A/S. (American College of Endocrinology Task Force on
Dr. Silvio E. Inzucchi reports that he has received Inpatient Diabetes and Metabolic Control). American
research grant support from Eli Lilly Company. College of Endocrinology position statement on inpatient
diabetes and metabolic control. Endocr Pract. 2004;10:
Dr. Faramarz Ismail-Beigi reports that he has no rel-
evant conflicts of interest.
10. American Diabetes Association. Standards of medical care
Dr. M. Sue Kirkman reports that she has no relevant in diabetes [published correction appears in Diabetes Care.
conflicts of interest. 2005;28:990]. Diabetes Care. 2005;28(suppl 1):S4-S36.
Dr. Mary T. Korytkowski reports that she has received 11. ACE/ADA Task Force on Inpatient Diabetes. American
consultant fees from Eli Lilly Company, Merck Co., College of Endocrinology and American Diabetes
Inc., and Novo Nordisk A/S and research grant support Association consensus statement on inpatient diabetes and
from sanofi-aventis U.S. LLC. glycemic control. Endocr Pract. 2006;12:458-468.
Dr. Etie S. Moghissi reports that she has received 12. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of
consultant fees from and is a stockholder with Amylin tight glucose control in critically ill adults: a meta-analy-
Pharmaceuticals, Inc. and Novo Nordisk A/S. sis [published correction appears in JAMA. 2008;301:936].
Dr. Guillermo E. Umpierrez reports that he has
13. Brunkhorst FM, Engel C, Bloos F, et al (German
received consultant fees from Merck Co., Inc. and con-
Competence Network Sepsis [SepNet]). Intensive insulin
sultant fees and research grant support from sanofi-aventis therapy and pentastarch resuscitation in severe sepsis. N
U.S. LLC. Engl J Med. 2008;358:125-139.
14. Finfer S, Chittock DR, Su SY, et al (NICE-SUGAR Study
REFERENCES Investigators). Intensive versus conventional glucose
control in critically ill patients. N Engl J Med. 2009;360:
1. American Diabetes Association. Economic costs of dia- 1283-1297.
betes in the U.S. in 2007 [published correction appears in 15. Krinsley JS, Grover A. Severe hypoglycemia in criti-
Diabetes Care. 2008;31:1271]. Diabetes Care. 2008;31: cally ill patients: risk factors and outcomes. Crit Care Med.
2. Centers for Disease Control and Prevention. National 16. Van den Berghe G, Wilmer A, Hermans G, et al.
diabetes fact sheet: general information and national esti- Intensive insulin therapy in the medical ICU. N Engl J Med.
mates on diabetes in the United States, 2007. Atlanta, GA: 2006;354:449-461.
US Department of Health and Human Services, Centers for 17. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive
Disease Control and Prevention, 2008. insulin therapy and mortality among critically ill patients:
3. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner a meta-analysis including NICE-SUGAR study data [pub-
RE. Unrecognized diabetes among hospitalized patients. lished online ahead of print March 24, 2009]. CMAJ. doi:
Diabetes Care. 1998;21:246-249. 10.1503/cmaj.090206.
Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4) 1
18. Malmberg K (DIGAMI [Diabetes Mellitus, Insulin before and during the era of intensive glycemic manage-
Glucose Infusion in Acute Myocardial Infarction] ment: six and one-half years experience at a university-
Study Group). Prospective randomised study of intensive affiliated community hospital. Semin Thorac Cardiovasc
insulin treatment on long term survival after acute myo- Surg. 2006;18:317-325.
cardial infarction in patients with diabetes mellitus. BMJ. 33. Malmberg K, Rydén L, Efendic S, et al. Randomized
1997;314:1512-1515. trial of insulin-glucose infusion followed by subcutaneous
19. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. insulin treatment in diabetic patients with acute myocardial
Continuous intravenous insulin infusion reduces the inci- infarction (DIGAMI study): effects on mortality at 1 year. J
dence of deep sternal wound infection in diabetic patients Am Coll Cardiol. 1995;26:57-65.
after cardiac surgical procedures [with discussion]. Ann 34. Malmberg K, Rydén L, Wedel H, et al (DIGAMI 2
Thorac Surg. 1999;67:352-362. Investigators). Intense metabolic control by means of insu-
20. Latham R, Lancaster AD, Covington JF, Pirolo JS, lin in patients with diabetes mellitus and acute myocardial
Thomas CS. The association of diabetes and glucose control infarction (DIGAMI 2): effects on mortality and morbidity.
with surgical site infections among cardiothoracic surgery Eur Heart J. 2005;26:650-661.
patients. Infec Control Hosp Epidemiol. 2001;22:607-612. 35. Cheung NW, Wong VW, McLean M. The Hyperglycemia:
21. Sala J, Masiá R, González de Molina FJ, et al (REGICOR Intensive Insulin Infusion in Infarction (HI-5) study; a ran-
Investigators). Short-term mortality of myocardial infarc- domized controlled trial of insulin infusion therapy for
tion patients with diabetes or hyperglycaemia during admis- myocardial infarction. Diabetes Care. 2006;29:765-770.
sion. J Epidemiol Community Health. 2002;56:707-712. 36. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intra-
22. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous operative insulin therapy versus conventional glucose man-
insulin infusion reduces mortality in patients with diabe- agement during cardiac surgery: a randomized trial. Ann
tes undergoing coronary artery bypass grafting. J Thorac Intern Med. 2007;146:233-243.
Cardiovasc Surg. 2003;125:1007-1021. 37. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress
23. Krinsley JS. Effect of intensive glucose management proto- hyperglycaemia and increased risk of death after myocar-
col on the mortality of critically ill adult patients [published dial infarction in patients with and without diabetes: a sys-
correction appears in Mayo Clin Proc. 2005;80:1101]. tematic overview. Lancet. 2000;355:773-778.
Mayo Clin Proc. 2004;79:992-1000. 38. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission
24. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically glucose and mortality in elderly patients hospitalized with
ill hospitalized patients: a meta-analysis of randomized, acute myocardial infarction: implications for patients with
controlled trials. Arch Intern Med. 2004;164:2005-2011. and without recognized diabetes. Circulation. 2005;111:
25. Ishihara M, Kojima S, Sakamoto T, et al (Japanese 3078-3086.
Acute Coronary Syndrome Study Investigators). Acute 39. Kosiborod M, Inzucchi SE, Krumholz HM, et al.
hyperglycemia is associated with adverse outcome after Glucometrics in patients hospitalized with acute myocar-
acute myocardial infarction in the coronary intervention dial infarction: defining the optimal outcomes-based mea-
era. Am Heart J. 2005;150:814-820. sure of risk. Circulation. 2008;117:1018-1027.
26. Mizock BA. Alterations in carbohydrate metabolism dur- 40. Goyal A, Mahaffey KW, Garg J, et al. Prognostic signifi-
ing stress: a review of the literature. Am J Med. 1995;98: cance of the change in glucose level in the first 24 h after
75-84. acute myocardial infarction: results from the CARDINAL
27. Devos P, Preiser JC, Mélot C (GluControl Steering study. Eur Heart J. 2006;27:1289-1297.
Committee). Impact of tight glucose control by intensive 41. Deedwania P, Kosiborod M, Barrett E, et al (American
insulin therapy on ICU mortality and the rate of hypogly- Heart Association Diabetes Committee of the Council
caemia: final results of the GluControl study [abstract]. on Nutrition, Physical Activity, and Metabolism).
Intensive Care Med. 2007;33:S189. Hyperglycemia and acute coronary syndrome: a scientific
28. De La Rosa GD, Donado JH, Restrepo AH, et al (Grupo statement from the American Heart Association Diabetes
de Investigacion en Cuidado Intensivo [GICIHPTU]). Committee of the Council on Nutrition, Physical Activity,
Strict glycaemic control in patients hospitalised in a mixed and Metabolism. Circulation. 2008;117:1610-1619.
medical and surgical intensive care unit: a randomised clin- 42. Pinto DS, Skolnick AH, Kirtane AJ, et al (TIMI Study
ical trial. Crit Care. 2008;12:R120. Group). U-shaped relationship of blood glucose with adverse
29. Finfer S, Delaney A. Tight glycemic control in critically ill outcomes among patients with ST-segment elevation myo-
adults. JAMA. 2008;300:963-965. cardial infarction. J Am Coll Cardiol. 2005;46:178-180.
30. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. 43. Svensson AM, McGuire DK, Abrahamsson P, Dellborg
Perioperative glycemic conrol and the risk of infectious M. Association between hyper- and hypoglycaemia and 2
complications in a cohort of adults with diabetes. Diabetes year all-cause mortality risk in diabetic patients with acute
Care. 1999;22:1408-1414. coronary events. Eur Heart J. 2005;26:1255-1261.
31. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, 44. Mehta SR, Yusuf S, Diaz R, et al (CREATE-ECLA Trial
Kanhere V, Starr A. Glucose control lowers the risk of Group Investigators). Effect of glucose-insulin-potassium
wound infection in diabetics after open heart operations. infusion on mortality in patients with acute ST-segment
Ann Thorac Surg. 1997;63:356-361. elevation myocardial infarction: the CREATE-ECLA ran-
32. Krinsley JS. Glycemic control, diabetic status, and mortal- domized controlled trial. JAMA. 2005;293:437-446.
ity in a heterogeneous population of critically ill patients
14 Consensus: Inpatient Hyperglycemia, Endocr Pract. 2009;15(No. 4)
45. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang 62. Derr RL, Hsiao VC, Saudek CD. Antecedent hypergly-
MC. Relationship of early hyperglycemia to mortality in cemia is associated with an increased risk of neutropenic
trauma patients. J Trauma. 2004;56:1058-1062. infections during bone marrow transplantation. Diabetes
46. Jeremitsky E, Omert LA, Dunham CM, Wilberger J, Care. 2008;31:1972-1977.
Rodriguez A. The impact of hyperglycemia on patients 63. Hammer MJ, Casper C, Gooley TA, O’Donnell PV,
with severe brain injury. J Trauma. 2005;58:47-50. Boeckh M, Hirsch IB. The contribution of malglycemia
47. Gale SC, Sicoutris C, Reilly PM, Schwab CW, Gracias to mortality among allogeneic hematopoietic cell trans-
VH. Poor glycemic control is associated with increased plant recipients. Biol Blood Marrow Transplant. 2009;15:
mortality in critically ill trauma patients. Am Surg. 2007;73: 344-351.
454-460. 64. Shim YH, Kweon TD, Lee JH, Nam SB, Kwak YL.
48. Vogelzang M, van der Horst ICC, Nijsten MW. Intravenous glucose-insulin-potassium during off-pump
Hyperglycaemic index as a tool to assess glucose control: a coronary artery bypass surgery does not reduce myocardial
retrospective study. Crit Care. 2004;8:R122- R127. injury. Acta Anaesthesiol Scand. 2006;50:954-961.
49. Duane TM, Ivatury RR, Dechert T, et al. Blood glucose 65. Wintergerst KA, Buckingham B, Gandrud L, Wong
levels at 24 hours after trauma fails to predict outcomes. J BJ, Kachce S, Wilson DM. Association of hypoglycemia,
Trauma. 2008;64:1184-1187. hyperglycemia, and glucose variability with morbidity and
50. Cochran A, Davis L, Morris SE, Saffle JR. Safety and
death in the pediatric intensive care unit. Pediatrics. 2006;
efficacy of an intensive insulin protocol in a burn-trauma
intensive care unit. J Burn Care Res. 2008;29:187-191.
66. Palacio A, Smiley D, Ceron M, et al. Prevalence and clini-
51. Wahl WL, Taddonio M, Maggio PM, Arbabi S, Hemmila
cal outcome of inpatient hyperglycemia in a community
MR. Mean glucose values predict trauma patient mortality.
pediatric hospital. J Hosp Med. 2008;3:212-217.
J Trauma. 2008;65:42-47.
52. Pasternak JJ, McGregor DG, Schroeder DR, et al 67. Faustino EV, Apkon M. Persistent hyperglycemia in criti-
(IHAST Investigators). Hyperglycemia in patients under- cally ill children. J Pediatr. 2005;146:30-34.
going cerebral aneurysm surgery: its association with long- 68. Branco RG, Garcia PC, Piva JP, Casartelli CH, Seibel V,
term gross neurologic and neuropsychological function. Tasker RC. Glucose level and risk of mortality in pediatric
Mayo Clin Proc. 2008;83:406-417. septic shock. Pediatr Crit Care Med. 2005;6:470-472.
53. Mowery NT, Gunter OL, Guillamondegui O, et al. Stress 69. Tuggle DW, Kuhn MA, Jones SK, Garza JJ, Skinner S.
insulin resistance is a marker for mortality in traumatic brain Hyperglycemia and infections in pediatric trauma patients.
injury [with discussion]. J Trauma. 2009;66:145-153. Am Surg. 2008;74:195-198.
54. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy 70. Falcao G, Ulate K, Kouzekanani K, Bielefeld MR,
K, Scalea TM. Admission hyperglycemia is predictive Morales JM, Rotta AT. Impact of postoperative hyper-
of outcome in critically ill trauma patients. J Trauma. glycemia following surgical repair of congenital cardiac
2005;59:80-83. defects. Pediatr Cardiol. 2008;29:628-636.
55. Bochicchio GV, Joshi M, Bochicchio KM, et al. Early 71. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et
hyperglycemic control is important in critically injured al. Early insulin therapy in very-low-birth-weight infants.
trauma patients. J Trauma. 2007;63:1353-1358. N Engl J Med. 2008;359:1873-1884.
56. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyper- 72. Vlasselaers D, Milants I, Desmet L, et al. Intensive insu-
glycemia as a prognostic indicator in trauma. J Trauma. lin therapy for patients in paediatric intensive care: a pro-
2003;55:33-38. spective, randomised controlled study. Lancet. 2009;373:
57. Collier B, Diaz J Jr, Forbes R, et al. The impact of a nor- 547-556.
moglycemic management protocol on clinical outcomes in 73. Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early
the trauma intensive care unit [with discussion]. JPEN J postoperative glucose control predicts nosocomial infec-
Parenter Enteral Nutr. 2005;29:353-359. tion rate in diabetic patients. JPEN J Parenter Enteral Nutr.
58. Shin S, Britt RC, Reed SF, Collins J, Weireter LJ, 1998;22:77-81.
Britt LD. Early glucose normalization does not improve 74. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein
outcome in the critically ill trauma population. Am Surg. HC. Stress hyperglycemia and prognosis of stroke in nondi-
2007;73:769-772. abetic and diabetic patients: a systematic overview. Stroke.
59. Bilotta F, Caramia R, Cernak I, et al. Intensive insulin 2001;32:2426-2432.
therapy after severe traumatic brain injury: a randomized 75. Bruno A, Gregori D, Caropreso A, Lazzarato F, Petrinco
clinical trial. Neurocrit Care. 2008;9:159-166. M, Pagano E. Normal glucose values are associated with
60. Davidson JA, Wilkinson A (International Expert Panel a lower risk of mortality in hospitalized patients. Diabetes
on New-Onset Diabetes After Transplantation). New-
Onset Diabetes After Transplantation 2003 International
76. Norhammar AM, Rydén L, Malmberg K. Admission
Consensus Guidelines: an endocrinologist’s view. Diabetes
plasma glucose: independent risk factor for long-term
prognosis after myocardial infarction even in nondiabetic
61. Fuji S, Kim SW, Mori S, et al. Hyperglycemia dur-
patients. Diabetes Care. 1999;22:1827-1831.
ing the neutropenic period is associated with a poor out-
77. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose con-
come in patients undergoing myeloablative allogeneic
hematopoietic stem cell transplantation. Transplantation. trol and mortality in critically ill patients. JAMA. 2003;290: